Haut
  • Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Bodet-Milin C, Ferrer L, Rauscher A, Masson D, Rbah-Vidal L, Faivre-Chauvet A, Cerato E, Rousseau C, Hureaux J, Couturier O, Salaün PY, Goldenberg DM, Sharkey RM, Kraeber-Bodéré F, Barbet J (2015) Front Med (Lausanne), 2 : 84.
  • Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging. Colombié M, Gouard S, Frindel M, Vidal A, Chérel M, Kraeber-Bodéré F, Rousseau C, Bourgeois M (2015) Front Med (Lausanne). 2 : 58.
  • Single-Dose Anti-CD138 Radioimmunotherapy : Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, Gaschet J, Chérel M (2015) Front Med (Lausanne), 2 : 76.
  • Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy ? Guérard F, Barbet J, Chatal JF, Kraeber-Bodéré F, Chérel M, Haddad F. (2015) Q J Nucl Med Mol Imaging. 59 : 161-167. (IRON et ArronaxPlus)
  • A pretargeting system for tumor PET imaging and radioimmunotherapy Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. (2015) Front Pharmacol. 6 : 54.
  • Radioimmunotherapy : from current clinical success to future industrial breakthrough ? Kraeber-Bodéré F, Barbet J, Chatal JF (2015) J Nucl Med. 2015 Oct 29.